March 2014 in “Journal of The American Academy of Dermatology” Azathioprine may be an effective treatment for severe hair loss.
2 citations
,
September 2024 in “Internal Medicine Journal” Upadacitinib helped regrow hair and maintain ulcerative colitis remission.
October 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Early genetic testing and zinc therapy are crucial for managing acrodermatitis enteropathica effectively.
October 2025 in “OPAL (Open@LaTrobe) (La Trobe University)” Early genetic testing and zinc therapy are crucial for managing acrodermatitis enteropathica in infants.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
December 2024 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Deucravacitinib helped a man regrow hair significantly.
2 citations
,
May 2017 in “Journal of the American Academy of Dermatology” Tofacitinib helped a 19-year-old regrow hair after other treatments failed.
7 citations
,
July 2025 in “The Journal of Physiology” C-tactile nerves are sensitive to hair movement.
5 citations
,
October 2024 in “Reumatismo” Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.
January 2018 in “Figshare” Curcuma aeruginosa extract lotion effectively reduces underarm hair growth.
86 citations
,
December 2002 in “Tissue Antigens” A specific gene change is linked to severe hair loss.
May 2023 in “Journal of Applied Cosmetology” The Annurca apple supplement significantly improved hair growth in people with hair loss.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The model improves understanding of androgen interactions by focusing on signal intensity and system capacity.
April 2026 in “Zenodo (CERN European Organization for Nuclear Research)” The model improves understanding of androgen interactions by focusing on signal intensity and system capacity.
28 citations
,
September 2002 in “The Journal of Comparative Neurology” Presynaptic inhibition of certain nerve fibers in cats is mainly controlled by GABA and glycine.
Avicennia marina extract and avicequinone C can potentially promote hair growth and treat hair loss by interfering with hair loss mechanisms and boosting growth factors.
3 citations
,
August 2020 in “Case Reports in Dermatology” Tofacitinib treatment significantly improved a patient's psoriasis, psoriatic arthritis, and alopecia universalis.
2 citations
,
July 2025 in “Scientific Reports” Acinetobacter strain A1-4-2 can safely clean water pollutants.
19 citations
,
May 2014 in “Molecules” Avicequinone C, a compound found in the Avicennia marina plant, can reduce hair loss by inhibiting a hormone linked to androgenic alopecia.
July 2025 in “The Journal of Physiology” C-tactile afferents are linked to emotional touch and social bonding through hair movement.
I'm sorry, but I cannot process the document as it is not in English. If you provide an English summary or conclusion, I can help summarize that for you.
April 2021 in “Research Square (Research Square)” N-acetylcysteine improved symptoms of trichotillomania and bulimia.
26 citations
,
September 2009 in “Clinical genetics” Arab APS1 patients have unique and recurrent AIRE gene mutations.
November 1998 in “Hair transplant forum international” The document's conclusion cannot be summarized because the content is not understandable.
January 2017 in “DOAJ (DOAJ: Directory of Open Access Journals)” Botulinum toxin type A did not help regrow hair in severe alopecia cases.
November 2022 in “Zenodo (CERN European Organization for Nuclear Research)”
October 2023 in “FASEB bioAdvances” Akkermansia muciniphila may help prevent testosterone-related hair loss.
November 2025 in “Bioactive Materials” TQC shows promise for better hair regrowth in treating hair loss.
October 2025 in “Frontiers in Medicine” Zinc supplements improved symptoms in a Uyghur infant with a rare genetic disorder affecting zinc absorption.
1 citations
,
April 2025 in “Skin Health and Disease” Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.